Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethosuximide for Treatment-Resistant Depression
NCT03887624Phase 1Completed
- Sponsor
- Zhejiang University
- Start
- May 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ethosuximide in treatment-resistant depression (TRD) (2 arms), sponsored by Zhejiang University. Primary endpoint: Montgomery and Asberg Depression Rating Scale at 43 days. Started May 2019; status: completed.
02
Drugs
ethosuximide
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT03887624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03887624.